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CHILDHOOD CANCER FERTILITY PRESERVATION DECISION AID: 
DEVELOPMENT AND FIELD TESTING 
 
JESSICA L. GRASSO 
ABSTRACT 
 There is an increased number of childhood cancer survivors living into adulthood. 
As more survivors live into adulthood, researchers have been able to study and better 
understand the late effects of cancer treatment. A well-known late effect of cancer 
treatment is the risk of infertility. Cancer-related infertility is a source of distress to 
cancer survivors. There have been many advances to fertility preservation over the last 
few years and there are now multiple options available for both men and women. Despite 
the improved understanding of the risk of cancer-related infertility and advances to 
fertility preservation treatment, these services remain underutilized by cancer patients. It 
is known that discussing fertility preservation options with newly diagnosed cancer 
patients improves survivors’ long-term quality of life and reduces decisional regret, 
regardless of if they pursue fertility preservation treatment. Survivors often report that the 
risk of treatment-related infertility and/or available fertility preservation options was 
often inadequately or not discussed with them at the time of diagnosis. The use of fertility 
preservation decision aids for adult patients newly diagnosed with cancer have been 
proven to be effective at improving participants’ knowledge surrounding fertility 
preservation, reducing decisional conflict, and reducing long term decisional regret. A 
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fertility preservation decision aid has not yet been developed for use by adolescents 
newly diagnosed with childhood cancer. 
This study aims to engage survivors and providers to develop a fertility 
preservation decision aid to improve the decision quality of adolescents newly diagnosed 
with childhood cancer who are determining their preferences on accepting a referral to a 
fertility specialist. This study then proposes to field test the decision aid with newly 
diagnosed patients. The use of a decision aid will lead adolescents with childhood cancer 
to have increased knowledge on the risk of infertility and the fertility preservation options 
available. This study also aims to lower participants’ levels of decisional conflict about 
their fertility preferences.  
There is a need to incorporate the use of a fertility preservation decision aid into 
childhood cancer treatment. If this decision aid proves effective, referral to the fertility 
preservation decision aid may become common practice at the time of initial diagnosis. If 
the decision aid is effect at improving decision quality and reducing decisional conflict, 
survivors may experience long-term benefits including improved quality of life and 
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Improved cancer treatments are resulting in an increased number of survivors of 
childhood cancer living into adulthood. There are approximately 350,000 adult survivors 
of childhood cancer living in the United States.1 Despite a 65% reduction in the death rate 
of childhood cancer from 1970 to 2015 in the United States, it remains the leading cause 
of death by disease in children.2 With more survivors of childhood cancer living into 
adulthood, there have been increased opportunities to learn about the late effects of 
cancer treatment.  
One of the known late effects of cancer treatment is the risk of infertility. The 
Childhood Cancer Survivor Study found that compared to their siblings, female survivors 
of childhood cancer were less likely to become pregnant and male survivors were less 
likely to father a pregnancy.3,4 Given the paucity of data regarding rates of infertility 
following current cancer treatments and the large number of factors that influence 
fertility, oncologists have difficulty providing precise guidance to patients about their 
individual risk for treatment-related infertility.5 Thus, fertility preservation should be 
discussed with all childhood cancer patients.  
There is a range of fertility preservation options available depending on the 
patient’s sex, age, pubertal status, relationship status, and personal preferences. The 
treating oncologist should be prepared to discuss the risk of infertility, fertility 
preservation options, and be able to refer patients to fertility specialists when appropriate. 
Most survivors report that, at the time of diagnosis, fertility was not an issue that they or 
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their parents considered important, however, fertility gained importance for them as they 
got older.6 There has been limited research conducted that explores the extent and content 
of fertility preservation discussions between pediatric oncologists and childhood cancer 
patients and their families.7  
There is evidence to support the use of decision aids to inform, educate, and guide 
the medical decision-making process. Fertility preservation decision-aids have been 
developed and proven effective for parents of teen girls newly diagnosed with cancer, as 
well as young women with breast cancer.8,9 Research is currently being conducted for 
young adult females with cancers of varying types that utilizes a multicomponent 
oncofertility decision support intervention.10 This intervention incorporates provider 
education, patient access to a decision aid website, and follow-up navigation support.10 
However, there is no research available investigating the use of decision aids for fertility 
preservation in childhood cancer. 
Statement of the Problem 
Cancer-related infertility has been shown to be  a cause of distress and decreased 
quality of life for cancer survivors.11 Fertility preservation remains underutilized despite 
an increased understanding of the risk of treatment associated infertility and an increased 
availability of fertility preservation methods.11  Research has shown that discussing 
fertility preservation improves survivors’ long-term outcomes, including quality of life 
and levels of decisional regret.11 These improved outcomes are experienced whether or 
not patients choose to pursue fertility preservation treatment.11 This may be the result of 
having been well-informed and engaged in the decision-making process.11 Barriers that 
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limit the discussions and decisions about fertility preservation include but are not limited 
to the late delivery of pertinent information, psychological stress, fear of delaying cancer 
treatment, and cost. 
The American Society of Clinical Oncology recommends discussing the risk of 
treatment-related infertility, as well as fertility preservation options, as early as possible 
with patients or their caregivers.12 At the time these guidelines were released in 2006, 
research showed that many providers were not discussing the risk of infertility or were 
doing so sub-optimally.5 After the guidelines had been in place for approximately three 
years, less than 60% of oncologists discussed fertility with patients/families and less than 
40% of treating physicians referred patients interested in fertility preservation to 
reproductive specialists.13 Thus, many childhood cancer patients and their families are 
either not being told about the risk of infertility due to cancer treatment or are 
inadequately having fertility preservation options discussed prior to the initiation of 
treatment.  
There is a need to improve patient-clinician communication and the decision-
making process regarding fertility preservation in pediatric oncology settings. The use of 
a decision aid may help adolescents newly diagnosed with cancer become aware of the 
risk of infertility, the fertility preservation options available, and make informed choices 
that could minimize future regret.  
Hypothesis 
The use of a fertility preservation decision aid will improve the decision quality of 
adolescents newly diagnosed with childhood cancer who are determining their 
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preferences on accepting a referral to a fertility specialist. The use of a decision aid will 
lead to increased knowledge on the risk of infertility and the fertility preservation options 
available as well as lower levels of decisional conflict surrounding their fertility 
preferences.   
Objectives and specific aims 
The objective of this study is to assess the effect of a fertility preservation decision aid, 
for adolescents newly diagnosed with childhood cancer.  Specifically, this study aims: 
• To assess the effect of a fertility preservation decision aid on decision quality (i.e. 
fertility preservation knowledge), for adolescents newly diagnosed with childhood 
cancer.  
• To assess the effect of a fertility preservation decision aid on the decisional 
conflict surrounding the fertility preferences of an adolescent newly diagnosed 




REVIEW OF THE LITERATURE 
Overview 
Childhood Cancer 
Childhood cancer, or pediatric cancer, is a cancer that is found in children (birth 
to 14 years of age) and adolescents (15 to 19 years of age).14 In 2018, it is estimated that 
10,590 new cancer cases will be diagnosed in children 0-14 years of age.15 Of these, 
1,180 will die from their disease.2 In addition, 5,190 adolescents from 15 to 19 years of 
age will be given a new diagnosis of childhood cancer.16 In the United States, 
approximately 1 in 416 children with be diagnosed with cancer by the age of 15 and 1 in 
285 children will be diagnosed with cancer by the age of 20.16,17 Globally, there are 
greater than 300,000 children diagnosed with cancer each year.16 The overall incidence of 
childhood cancer was stable over the past 5 data years, after increasing slightly by 0.6% 
per year since 1975.2  
Survival rates for childhood cancer have increased dramatically in the last forty 
years. In the United States, there has been a 65% reduction in the death rate from 1970 to 
2015.2 In children, aged birth to 14, the 5 year relative survival rate for all International 
Classification of Childhood Cancer (ICCC) combined improved from 58% during the 
mid-1970s to 83% in 2007.2 In adolescents, ages 15 to 19, the 5 year relative survival rate 
for all ICCC combined increased from 68% in the mid-1970s to 84% during 2007 
through 2013.2 However, survival rates vary for each type of childhood cancer (Table 1). 
The 5-year survival rate for acute lymphoblastic leukemia (ALL) diagnosed between the 
ages of 15 and 19 years has increased from 50% in the 1990s to 74% in 2007.18 Improved 
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treatments have also increased the 5-year survival rate for non-Hodgkin lymphoma 
diagnosed before the age of 20 from less than 50% in the late 1970s to 89% in 2007.18 In 
the United States, there are approximately 350,000 living adult survivors of childhood 
cancer.1 
Table 1. Five-Year Relative Survival Rate (%) for the Most Common Childhood 
and Adolescent Cancers, United States, 2007 to 2013 (adapted from Siegel et al.)2 
 
 Birth to 14 years of age 15 to 19 years of age 
All ICC groups combined 83.0 84.2 
Lymphoid leukemia 90.5 74.2 
Acute myeloid leukemia 65.1 61.5 
Hodgkin lymphoma 97.6 96.1 
Central nervous system neoplasms 72.5 78.9 
Neuroblastoma & other peripheral 
nervous cell tumors 
79.0 62.8 
Renal tumors 91.8 72.7 
Osteosarcoma 69.8 65.5 
Rhabdomyosarcoma 69.8 45.9 
Germ cell and gonadal tumors 92.4 92.0 
Thyroid carcinoma 99.4 99.5 




There are various types of childhood cancer which vary by age group. The most 
common childhood cancer types in patients age birth to 14 can be seen in Table 2, while 
those in patients age 15 to 19 can be seen in Table 3. 
Table 2. Most Common Types of Childhood Cancer age birth to 14 years of age2 
 












(non-Hodgkin: 6%/Hodgkin lymphoma 3%) 














Table 3. Most Common Types of Childhood Cancer age 15 to 19 years of age2 
 
 Percentage of Childhood Cancer 





Germ cell and gonadal tumors 11% 
Skin melanoma 4% 
 
In childhood cancer, for patients age birth to 14 years of age, the incidence rates 
are higher in males than in females, however, survival rates are similar.17  In adolescent 
patients age 15-19 years of age, incidence rates are about equal, while mortality rates are 
lower in females.17  This difference may be a result of the different types of cancer that 
occur in males compared to those that are more common in females of this age group.17 
Incidence rates of childhood cancer also vary among race and ethnicity. Caucasian and 
Hispanic children have the highest incidence rates of childhood cancers.17 Despite 
increased incidence among those racial groups, mortality rates are highest among Asian 
American/Pacific Islander and African American children.17 Socioeconomic status, health 
insurance status, timely diagnosis, quality of treatment and supportive care, as well as 
genetic factors may contribute to the racial and ethnic disparities in mortality rates.17 The 
lowest incidence and mortality rates are reported in American Indian/Alaska Native 
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children.17 From a global perspective, when all types of childhood cancer are considered 
together, there is a higher incidence in industrialized countries than in developing 
countries.17   
 Most types of childhood cancer are believed to develop from genetic mutations 
that result in uncontrolled cell growth.18 In contrast to adult cancers, where many have 
known or preventable causes, most childhood cancers have unknown causes.15,17 Most 
childhood cancer results from acquired idiopathic DNA mutations.19 Approximately 5% 
of all childhood cancers are from inherited genetic mutations.18 There are known genetic 
factors linked to Wilms tumor and retinoblastoma.17  Few environmental exposures have 
been found to be associated with increased risks of childhood cancer, in contrast to adult 
cancers.18 There are a few known risk factors that have been shown to be associated with 
certain types of childhood cancers. Patients with exposure to ionizing radiation have an 
increased risk of developing leukemia due to resulting damage to DNA.15,17,18  This 
includes parental radiation exposure during pregnancy.17  Children who have undergone 
solid organ transplants are at an increased risk for non-Hodgkin lymphoma due to the 
immunosuppressive drugs used to prevent organ rejection.15 There has also been a proven 
association between Down syndrome and the development of leukemia; children with 
Down syndrome have a 10 to 20 times greater risk than children without Down 
syndrome.15,18 The International Agency for Research on Cancer has found that there is 
an increased risk of hepatoblastoma and possibly leukemia with parental smoking.17   
Children born to parents who were treated for a childhood cancer caused by a non-
inherited mutation have not been found to be at an increased risk of developing cancer 
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themselves.18 It is currently believed that most cases of childhood cancer are not linked to 
external exposures but rather are due to the inherent risk associated with the complex 
process of normal development.17  
 Treatment for each type of childhood cancer varies. Mainstays of cancer therapy 
include chemotherapy, radiation therapy, bone marrow or stem cell transplant, surgery, 
immunotherapy, and targeted therapy.20 Patients may also be treated with multiple 
therapies, known as combination therapy.20 More than 60% of children with childhood 
cancer are treated as part of a clinical trial.21 During clinical trials, protocols are based on 
the standard of care with slight variations that are hypothesized to reduce side effects or 
improve success.20 The determination of a treatment plan takes into consideration many 
factors, including what has been proven to be most effective for that type and stage of 
cancer, the location of the cancer, possible side effects and late effects, and the patient’s 
preferences and overall health.21 Late effects are long-term effects from cancer treatment 
that may not be known until years after the completion of treatment.20 For purposes of 
this paper, the standard of care for each type of childhood cancer will not be discussed 
but this information can be found on the National Cancer Institute website under “PDQ 
Cancer Information Summaries: Pediatric Treatment.”22 A brief overview of the 
mainstays of childhood cancer therapy will be provided, followed by a discussion on the 
late effects of cancer therapy, specifically infertility.  
 Chemotherapy is a medication that attacks rapidly dividing cells, including cancer 
cells and healthy cells.20 There are three main mechanisms of how chemotherapy works 
to treat cancer: preventing cellular components needed for cells to divide from copying; 
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replacing or eliminating essential enzymes or nutrients the cancer cells need to survive; 
or triggering cells to enter apoptosis.20 Some chemotherapy agents are also known to 
cause permanent side effects after being used beyond a certain summative quantity.20 
There are regulations in place to monitor the use of these drugs. Chemotherapy regimens, 
including drug choice, administration route, dosage, and duration, are determined based 
on the type and stage of the cancer, tumor size and location, the cancer’s response to 
chemotherapy, the child’s weight or body surface area, risk of side effects, and any 
previous cancer treatment.20,23 
 The timing of chemotherapy treatment varies. Neoadjuvant chemotherapy can be 
given prior to surgery or radiation therapy with the goal of shrinking the tumor.23 
Adjuvant chemotherapy is the use of chemotherapy following surgery or radiation 
therapy to kill any remaining cancer cells.23 Chemotherapy can also be used as a single 
treatment agent, as is common in leukemia and lymphoma.23 In cases of recurrent or 
metastatic cancer, chemotherapy is commonly used.23 Chemotherapy can be administered 
in various ways, including intravenously, intrathecally, intramuscularly, intraperitoneal, 
intracavitary, subcutaneously, or orally.20 
 Because chemotherapy acts on rapidly dividing cells, including healthy cells, 
there are many side effects associated with this treatment modality. These side effects are 
usually temporary and resolve once treatment is completed. Factors that influence the 
occurrence of side effects include the chemotherapy agent used, the dose, and overall 
health of the patient.20 Some common side effects include anemia, bruising, bleeding, 
diarrhea, constipation, fever, hair loss, mouth and throat soars, nausea and vomiting, as 
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well as organ damage (most commonly the heart, lungs, kidneys, liver, and brain).20 
Chemotherapy can also cause late effects.   
 Radiation therapy uses high-energy x-rays or charged particles, such as photons, 
to destroy cancer cells.21 Similar to chemotherapy, radiation works by destroying or 
damaging rapidly growing cells.20 However, unlike chemotherapy, radiation therapy is 
most commonly targeted at the site of the tumor, minimizing damage throughout the 
body.20 Exceptions to this are radioimmunotherapy and forms of radiation therapy in 
which a patient swallows or receives an injection of radioactive material that targets 
cancer cells.24 These forms are considered systemic radiation therapy although they still 
target cancer cells.24 As with chemotherapy, radiation can be given prior to or after other 
treatment modalities or as a single treatment modality.  
Radiation can be delivered both externally and internally. External beam radiation 
is more commonly used in the treatment of childhood cancer.20 In this form, radiation is 
delivered from a machine, known as a linear accelerator, from outside of the body.20,24 
Radiation therapy can damage nearby healthy cells that are in the radiation field. To 
reduce damage to healthy cells, the radiation field is precisely measured using computer 
software, which adjusts the beam’s size and shape to target the tumor.20,24 Radiation 
therapy is commonly given five days a week for a number of weeks (ranging from one to 
ten weeks). This allows high enough doses of radiation to enter the body to kill the 
cancer, while allowing healthy cells time to recover.20 Internal radiation therapy is also 
known as brachytherapy. In this form of radiation therapy, radioactive material is placed 
into the cancer or surrounding tissue using permanent or temporary implants.24 
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  Radiation beams passing through healthy cells can result in side effects.20 The 
onset of side effects is typically seen during the second or third week of therapy and can 
last several weeks after the final radiation treatment.20 Common side effects regardless of 
radiation site include fatigue, decreased blood counts, and radiation dermatitis.20 Other 
side effects are specific to the location of the radiation therapy. Late effects of radiation 
therapy regardless of site of radiation include cataracts and secondary cancers.20 There 
are also a range of site specific late effects, including infertility with radiation to the 
brain, head or neck, abdomen, and pelvis.20 
 Bone marrow transplant (BMT) is also referred to as stem cell transplant or 
hematopoietic stem cell transplant.20 The goal of BMT is to destroy cancer cells in the 
bone marrow, blood, and other parts of the body using high doses of chemotherapy 
and/or radiation and then replace the blood stem cells with healthy hematopoietic stem 
cells that can create new, healthy bone marrow and thus blood cells.20,21 BMT is used to 
treat childhood cancer when the normal stem cells in the bone marrow have been 
destroyed, such as in leukemia and lymphoma, or when the chance for cure with 
chemotherapy alone is unlikely.20,25 There are two main types of stem cell 
transplantation. Allogeneic stem cell transplants use stem cells from a Human 
Lymphocyte Antigen (HLA) matched donor. This type of stem cell transplant is 
commonly used in leukemias and some lymphomas.20 Autologous stem cell transplants 
use the patient’s own stem cells that are collected, frozen, and later thawed when needed 
for reinfusion.20 Autologous transplant is used for solid tumors, such as neuroblastoma, 
Hodgkin’s disease, and brain tumors.20 The use of allogeneic versus autologous stem cell 
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transplant is mainly determined by what type of childhood cancer the patient has.25 Prior 
to allogeneic or autologous transplant the patient is given preparative treatment called 
conditioning, which consists of high dose chemotherapy and sometimes whole body 
radiation.20 The conditioning process eliminates the child’s immune system placing them 
at high risk for infection during this time.20 Other common side effects that result from 
conditioning include anemia, thrombocytopenia, mucositis, and nausea.20 Late effects 
associated with BMT as a result of conditioning include growth and other endocrine 
problems, sterility, and organ damage to liver, kidneys, lungs, or heart, as well as 
cataracts.20 
 Surgery is often a part of the treatment plan for childhood cancer. Surgery serves 
many different purposes including diagnosis and tumor removal as well as supportive 
surgeries depending on the type, location, and extent of the cancer.20 Primary surgery 
refers to an operation that removes all or most of the tumor at one time.20 When used for 
tumor removal, the goal is to remove the tumor as well as some of the surrounding tissue 
in order to achieve negative margins. 20 It is sometimes necessary to use neoadjuvant 
chemotherapy or radiation therapy to shrink the tumor to make it easier to remove with 
surgery.20 Chemotherapy and radiation can also be used following the surgery to destroy 
any cancer cells left in the body.20 Second look, also known as exploratory surgery, is 
performed to allow physicians to get an inside look of the body to evaluate how well 
treatments have worked at killing the cancer cells.20 Supportive care surgery is done to 
aid in the treatment process. Examples of these procedures include having a central 
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venous line or a gastrostomy tube placed.20 Side effects of surgery vary depending on 
type, location, and stage of the cancer.21  
 Immunotherapy, also known as biologic therapy, is designed to boost the body’s 
own immune system to fight off the cancer cells.20,21 Immunotherapy uses biologic 
macromolecules, such as cytokines and checkpoint inhibitors, made by the body or in a 
laboratory to improve and restore the body’s natural defense mechanisms.21,26 These 
substances are known as biological response modifiers. By using naturally occurring 
substances, immunotherapy can also help lessen the side effects caused by other cancer 
treatments.20 Immunotherapy can include cytokines, interleukins, colony stimulating 
factors, and monoclonal antibodies.20,21,26 There are active immunotherapies and passive 
immunotherapies. Active immunotherapies work by stimulating the body’s immune 
system to work harder and more efficiently.20 Passive immunotherapies are generally 
man-made proteins given to supplement a patient’s immune system to help it work more 
effectively.20 Immunotherapy is most commonly used in combination with other cancer 
treatments.20 The side effects associated with immunotherapy vary based on the type of 
treatment used, however, it is common for patients to experience flu-like symptoms.20 
 Targeted therapies are a newer treatment modality for childhood cancers. These 
medications work by targeting processes that differ between cancer cells and healthy 
cells.20 By targeting the processes that allow cancer cells to grow and spread the goal is to 
disrupt the way cancer cells duplicate and interact with other cells.20 Examples of the 
processes targeted therapies act on include stopping blood vessels that supply cancer cells 
and interfering with signals that the cancer cells are dependent on to grow.20 Targeted 
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therapy can be used as a single treatment agent or as combination therapy. Targeted 
therapy has been shown to improve the effectiveness of chemotherapy and radiation 
when used in combination.20 As with the other treatments previously described, side 
effects vary with the substance that are used. However, with targeted therapy the side 
effects are generally milder and resolve at the completion of treatment.20 
 As discussed above, treatment for childhood cancer has evolved, leading to a 
substantial increase in the number of survivors. With the increased number of survivors 
living into adulthood, the late effects of treatment for childhood cancer are now more 
frequently experienced and as a result can be studied. Late effects manifest months to 
years after the completion of cancer treatment.27 It has been estimated that 60% to greater 
than 90% of childhood cancer survivors develop one or more chronic health conditions.27 
Twenty to 80% of childhood cancer survivors will experience severe or life-threatening 
complications during adulthood.27 The prevalence of late effects continues to rise as the 
elapsed time from cancer diagnosis increases. Survivors in the St. Jude Lifetime Cohort 
experienced an average of 17.1 chronic health conditions by the age of 50 years old.27 Of 
these health conditions, 4.7 were severe/disability, life threatening, or fatal. This 
compares to matched community controls who experienced an average of 9.2 chronic 
health conditions, 2.3 of which were severe/disabling, life threatening, or fatal.27 The 
Childhood Cancer Survivor Study (CCSS) revealed that by 50 years of age, 53.6% of 
survivors had a self-reported severe, disabling, life-threatening, or fatal health 
condition.27 This was in contrast to the sibling control group at 19.8%.27 These chronic 
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health conditions were shown to be associated with a higher prevalence of emotional 
distress symptoms compared to population controls.27 
 In a broad sense, late effects involve growth and development, organ function, 
reproductive capacity and health of offspring, secondary carcinogenesis, and 
psychosocial sequelae.27 There are many factors influencing who is at risk for late effects, 
including tumor-related factors, treatment-related factors, and host-related factors.27,28 
Tumor-related factors include tumor location, direct tissue effects, tumor-induced organ 
dysfunction, and mechanical effects.27,28 Treatment-related factors include therapeutic 
exposure, dose-intensity and cumulative dose, agent type, site, and use of combination 
therapy.27,28 Host-related factors include the patient’s sex, genetic predisposition, 
premorbid health state, developmental status, age at diagnosis, time from 
diagnosis/therapy, inherent tissue sensitivities and capacity for normal tissue repair, 
hormonal milieu, function of organs not affected by treatment, socioeconomic status, and 
health habits.27,28 Due to the unique risks childhood cancer survivors face and the wide 
range of late effects that have been shown to be associated with cancer therapy, long-term 
follow-up needs to be a regular component of survivors’ health practices.  
Late Effects of the Reproductive System 
 Infertility is one of the most common and life altering complications experienced 
by survivors of childhood cancer.29,30 Cancer treatment that affects any component of the 
hypothalamic-pituitary axis or the gonads can cause late effects to the reproductive 
system.29 The CCSS found that compared to the sibling cohort, female participants were 
less likely to become pregnant (relative risk of ever pregnant 0.81; 95% Confidence 
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Interval [CI], 0.73-0.90)3  and male participants were less likely to father a pregnancy 
(hazard ration, 0.56; 95% CI, 0.49-0.63).4  Surgery, radiation therapy, and chemotherapy 
put a childhood cancer patient at the greatest risk for these late effects. There are many 
factors that go into assessing the risk of infertility, including the tissues and organs 
involved by the cancer and the type, dose, and combination of cytotoxic therapies used 
for treatment.28,29 Orchiectomy or oophorectomy, which are commonly performed for 
pediatric germ cell tumors can reduce germ cell numbers.28 Chemotherapy, especially 
with alkylating agents, is associated with a high risk of infertility.28 Factors influencing 
the risk of infertility associated with chemotherapy include cumulative dose, specific 
alkylating agent, the length of treatment, age at treatment, and the sex of the patient.28 
There is a well-established dose-related risk of chemotherapy with alkylating agents and 
gonadotoxicity.29 Currently, childhood cancer treatment protocols proactively restrict the 
cumulative doses of known gonadotoxic agents and preferentially incorporate agents with 
more favorable toxicity profiles.29 In general, girls maintain ovarian function at higher 
cumulative alkylating agent doses compared to the doses at which males maintain 
testicular function.29 The infertility risk associated with radiation exposure to the 
hypothalamic-pituitary axis or gonads is related to treatment volume, total dose, 
fractionation schedule, and age at treatment.28 Due to the large number of factors 
involved in treatment, as well as patient age, sex, and likely genetic factors that can 




 In both sexes, radiation to the hypothalamic-pituitary axis can lead to late effects 
of the reproductive system. Altered pubertal timing (precocious, early, rapid tempo) is 
more common after low dose radiation (18-24 Gy).29 Radiation can also lead to delayed 
puberty.29 Radiation at doses >30 Gy is more likely to lead to gonadotropin 
insufficiency.29  
 Female infertility can result from any treatment that decreases the number of 
primordial follicles, affects hormonal balance, or interferes with the functioning of the 
reproductive organs, including anatomic or vascular changes from surgery or radiation.5  
As mentioned above, female CCSS participants were less likely to become pregnant 
compared to the sibling cohort.3,29  
Chemotherapy with alkylating agents can lead to acute ovarian failure within 5 
years of diagnosis.29 However, the majority of female childhood cancer patients who are 
treated with risk-adapted combination chemotherapy will retain or recover ovarian 
function.29 CCSS participants who received a summed alkylating agent dose score of 
three to four or who were treated with Lomustine or cyclophosphamide were less likely 
to have ever been pregnant.3  An alkylating agent dose score is the total dose per square 
meter given of an alkylating agent. If a patient’s dose is within the first tertile, a score of 
one is assigned; if within the second tertile, a score of two is assigned; and if within the 
third tertile, a score of three is assigned.  
Radiation therapy impacting the female reproductive system (whole abdomen, 
pelvis, lumbosacral spine, hypothalamic-pituitary, total body) places the patient at risk for 
premature menopause.29 Radiation therapy can cause primary (direct) or secondary 
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(indirect) failure of the ovaries.31 Primary failure results from radiation that causes 
damage to the ovaries directly.31 Secondary failure of the ovaries results from radiation to 
the brain, specifically the pituitary gland, that alters the production of follicle stimulating 
hormone (FSH) and luteinizing hormone (LH).31 Reports from the CCSS showed that, in 
multivariate models among survivors, those who received a hypothalamic/pituitary 
radiation dose ≥30 Gy (RR, 0.61; 95% CI, 0.44 to 0.83) or an ovarian/uterine radiation 
dose greater than 5 Gy were less likely to have ever been pregnant (RR, 0.56 for 5 to 10 
Gy; 95% CI, 0.37 to 0.85; RR, 0.18 for >10 Gy; 95% CI, 0.13 to 0.26).3 With ovarian 
radiation doses >20 Gy, permanent ovarian failure is uniformly seen in childhood cancer 
patients.29 With abdominal radiation doses of 20-30 Gy, prepubertal girls may fail to 
undergo or complete pubertal development.29  
The older the patient is at the time of chemotherapy or radiation therapy, the 
higher the risk of acute ovarian failure and premature menopause.29 Prepubertal and 
adolescent girls have a greater complement of primordial follicles, leading to a more 
robust ovarian reserve than is in adults.29 Younger patients tend to have less damage to 
the ovaries than teenagers or young adults who receive equal doses.31 There is a 
considerable increase in the risk of acute ovarian failure in patients whose treatment 
includes both alkylating agent chemotherapy and abdominal/pelvic radiation or whose 
treatment includes dose-intensive alkylating agents for myeloablative conditioning before 
hematopoietic cell transplantation.29,32–35 
Aside from infertility, there are several other late effects to the female 
reproductive system. As previously mentioned, therapy can lead to failure to enter 
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puberty.31 Females who were already menstruating may have temporary cessation of 
menstrual cycles.31 Childhood cancer survivors are also at risk for premature menopause 
with unpredictable timing, so those who wish to have children are encouraged not to 
delay childbearing beyond their early thirties.31 Uterine vascular insufficiency and uterine 
growth impairment are late effects associated with radiation therapy affecting the uterus 
and most commonly seen in patients with a history of Wilms tumor and associated 
Müllerian anomalies.29 Radiation impacting the uterus also places childhood cancer 
survivors at a greater risk for spontaneous abortions, neonatal death, premature labor, low 
birth weight infant, fetal malposition, and dyspareunia.29 Radiation impacting the vagina 
can lead to vaginal fibrosis, vaginal stenosis, and dyspareunia.29 Unilateral oophorectomy 
can lead to premature menopause, sometimes referred to as surgical menopauase.29,31 
Bilateral oophorectomy always results in ovarian failure and infertility.31 Some childhood 
cancer patients may also require a hysterectomy leaving them unable to carry children.29 
The CCSS study identified several factors involved in determining who is at risk 
for female infertility following childhood cancer treatment. Because of the number of 
factors involved in determining the risk of infertility, it is difficult to determine which 
patients should be counseled on fertility preservation. This study provided treatment-
specific and dose-specific estimates for those at highest risk of infertility that can be used 
in counseling patients. The CCSS found that women age 15 to 44 years who receive a 
hypothalamic/pituitary radiation dose ≥ 30 Gy (RR, 0.61; 95% CI, 0.44 to 0.83), an 
ovarian/uterine radiation dose greater than 5 Gy (RR, 0.56 for 5 to 10 Gy; 95% CI, 0.37 
to 0.85; RR, 0.18 for > 10 Gy; 95% CI, 0.13 to 0.26), Lomustine, cyclophosphamide, or 
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any alkylating agent dose summed score of three or four are less likely to ever become 
pregnant.3 
As with females, male survivors of childhood cancer are at increased risk for 
infertility. The risk of male infertility following childhood cancer treatment is influenced 
by the patient’s age at the time of treatment, specific type and location of the cancer, and 
the treatment that is given.36 Male infertility frequently results from damage or depletion 
of germinal stem cells but it can also result from the disease itself (most commonly seen 
in patients with testicular cancer and Hodgkin’s lymphoma), anatomic problems such as 
those resulting in retrograde ejaculation or anejaculation, or from primary or secondary 
hormonal insufficiency.5 The male reproductive system is controlled by the pituitary 
gland, which releases FSH and LH beginning at puberty to signal to the testes to produce 
sperm and testosterone. Chemotherapy, especially with alkylating agents, radiation to the 
brain or testicles, or surgery involving the male reproductive tract put the male patient at 
risk for late effects to the reproductive system.36 Male CCSS participants were less likely 
overall to father a pregnancy than the sibling cohort but the magnitude of effect varied by 
cancer type.4,29 CCSS results showed that survivors of Hodgkin’s lymphoma were less 
likely to father a pregnancy (HR, 0.34; 95% CI, 0.28 to 0.41; P < .001), whereas those 
with Wilms tumor (HR, 0.99; 95% CI, 0.73 to 1.34; P = .95) or neuroblastoma (HR, 0.97; 
95% CI, 0.63 to 1.49; P = .88) were as likely as the siblings to father a pregnancy.4 
Treatment with alkylating agent chemotherapy or radiation impacting the male 
reproductive system (pelvic, testicular, hypothalamic-pituitary, total body, etc.) can lead 
to oligospermia or azoospermia.29 There is an increased risk of infertility in survivors 
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treated with a higher cumulative alkylating agent dose score, as well as in those treated 
with cyclophosphamide (third tertile HR, 0.42; 95% CI, -0.31 to 0.57) or procarbazine 
(second tertile HR, 0.48; 95% CI, -0.26 to 0.87; third tertile HR, 0.17; 95% CI, -0.07 to 
0.41).4 This is in comparison to the control cohort of siblings where HR was 0.91 (95% 
CI, 0.73 to 1.14; P = .41) for ever fathering a pregnancy.4 The likelihood of oligospermia 
or azoospermia is related to the total dose of alkylating chemotherapy used with higher 
doses having more potential to lead to infertility.36 There is also an increased risk of 
infertility when chemotherapy is used in combination with radiation.36  
Radiation can directly and indirectly affect testicular function. Radiation aimed 
directly at or near the testicles can damage the germ cells that are responsible for 
producing sperm and the Leydig cells that are responsible for testosterone production.36 
Decreased sperm counts can be observed 3 to 6 weeks after radiation, depending on the 
dose of radiation, and recovery (if at all) can take 1 to 3 years.27 The CCSS found that 
among survivors, the hazard ratio (HR) of fathering a pregnancy was decreased by 
radiation therapy of more than 7.5 Gy to the testes (HR, 0.12; 95% CI, -0.02 to 0.64) in 
comparison to the control cohort of siblings (HR, 0.91 95% CI, 0.73 to 1.14; P = .41).4 
Germ cells have been proven to be more sensitive to the effects of radiation aimed at the 
testes, in which irreversible damage occurred at doses as low as 2 to 4 Gy, compared to 
Leydig cells, which are resistant up to 20 to 30 Gy.27,36 Gonadal failure typically results 
when prepubertal boys are treated with >20 Gy radiation to the testes, whereas Leydig 
cell function is usually preserved in postpubescent males with radiation doses that do not 
exceed 30 Gy.29,37 Radiation to the pituitary gland in the brain can lead to low levels of 
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FSH and LH, which are needed to signal to the testicles to produce sperm and 
testosterone.36 Radiation to the pelvis, bladder, or spine also puts the patient at risk for 
retrograde ejaculation, anejaculation, and erectile dysfunction.29 
Conditioning with total body irradiation, high-dose alkylating agent 
chemotherapy, or both for stem cell transplantation carries a risk for infertility.27 Most 
male patients will maintain Leydig cell function and testosterone production but germ 
cell failure is common.27 
Surgical treatment can also lead to late effects of the reproductive system. 
Unilateral orchiectomy can lead to oligospermia.27 Treatment involving a bilateral 
orchiectomy leaves the patient infertile.29,36 Pelvic surgery, including retroperitoneal 
lymph node dissection or tumor dissection, cystectomy, and radical prostatectomy, can 
also lead to retrograde ejaculation, anejaculation, and erectile dysfuction.29,36 Cancer 
therapy can also lead to testosterone deficiency, also known as hypogonadism or Leydig 
cell failure.36 
 Several studies have been performed to address the issue of health risks to 
offspring of childhood cancer survivors. For purposes of this thesis, the risks to offspring 
of parents who have undergone cancer treatment will be reviewed only insofar as they 
might affect a person’s desire to pursue fertility preservation methods prior to therapy.5 
The Five Center Study evaluated the offspring born to adult survivors treated for 
childhood cancer before 1976.29,38 This study observed no statistically significant 
differences in the proportion of offspring with cytogenetic syndromes, single-gene 
defects, or simple malformations.29,38 Genetic disease occurred in 3.4% of 2,198 
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offspring of survivors, compared with 3.1% of 4,544 offspring of controls (P =0.33).29,38 
A population-based study through the Danish Cancer Registry compared the prevalence 
of abnormal karyotypes diagnosed in 2,630 offspring born to 4,676 adult survivors of 
childhood cancer to that of 5,504 born to 6,441 siblings.29,39 There was no significant 
difference in the proportion of children with abnormal karyotypes born to survivors 
(5.5/2,631.5 [0.21%]) and siblings (11.8/5,505.8 [0.21%]).29,39 There was also no 
significant difference in the prevalence of Down syndrome (relative risk [RR]=1.07; 95% 
CI 0.16-5.47) and Turner syndrome (RR=1.32; 95% CI 0.17-7.96).29,39 
 Another study through the Danish Cancer Registry evaluated the relationship of 
gonadal radiation and congenital malformations in offspring of childhood cancer 
survivors compared to the offspring of siblings.29,40 There was no significant difference at 
birth in the prevalence of congenital malformations in survivors’ offspring (44 cases, 
2.6%) compared to siblings’ offspring (140 cases, 2.3%).29,40 These ratios did not change 
when malformations diagnosed later in life were included.29,40  
A population-based study using nationwide registry data in Finland evaluated the 
potential of cancer treatment to cause germline mutations that might increase the risk of 
cancer in offspring of survivors diagnosed under the age of 35 years old between 1953 
and 2004.29,41 The prevalence of cancer among children born to 26,331 cancer survivors 
was compared to 58,155 children of siblings.29,41 The risk of cancer was increased 
(Standardized incidence ratio [SIR] 1.67; 95% CI 1.29-2.12) among the 9,877 children 
born after their parent’s diagnosis but the increase disappeared (SIR 1.03; 95% CI 0.74-
1.40) after exclusion of cases of hereditary cancer.29,41 The risk of cancer among the 
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offspring of siblings was not different from the offspring of patients with non-hereditary 
cancer (SIR 1.07; 95% CI 0.94-1.21).29,41 Collectively these studies indicate no increase 
in health risk to the offspring born to survivors of childhood cancer, including for 
congenital malformations, single gene disorders, chromosomal syndromes, or increased 
risk of offspring developing cancer, when parents do not have a hereditary form of 
cancer.29   
Fertility Preservation 
 Fertility preservation (FP) options are important to consider in all childhood 
cancer patients. The discussion of FP should take place prior to the initiation of therapy. 
Oncology treatment plans frequently change course and go from unlikely to cause 
infertility to definite without enough time to reassess the patient’s options.42 In 2006, the 
American Society of Clinical Oncology (ASCO) released the ASCO Recommendations 
on Fertility Preservation in Cancer Patients based on a systematic review of the literature 
from 1987 to 2005.5 ASCO recommends oncologists discuss the risk of infertility with all 
patients being treated during their reproductive years as part of the patient education and 
informed consent process.5 ASCO also recommends that oncologists should discuss FP 
options and be able to refer interested patients to reproductive specialists.5 In the case of 
childhood cancer, the possibility of treatment-related infertility should be discussed with 
the parents and the child, if appropriate. At the time ASCO released their 
recommendations in 2006, they found that many oncologists either did not discuss the 
possibility of treatment-related infertility or did so sub-optimally.5 Several surveys have 
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found fewer than half of oncologists in the United States follow the ASCO guidelines and 
those that do rarely refer patients to reproductive specialists.43  
As previously discussed, it is difficult to estimate the risk of infertility after 
treatment for cancer. For this reason, it is important that FP is discussed with all 
childhood cancer patients and their parents. Given the paucity of data regarding rates of 
infertility following current cancer treatments and the large number of factors that 
influence fertility, oncologists have difficulty providing precise guidance to patients 
about their individual risk for treatment-related infertility.5 The field of FP is also quickly 
changing as new advancements are made. It is the responsibility of the treating oncologist 
to discuss FP with their patients and the patient’s parents. The treating physician should 
be able to refer them to the necessary resources should they be interested in pursuing FP 
options or discussing the options further. Most families are unaware of the risk of 
treatment-related infertility that a childhood cancer patient faces and rely on the provider 
to inform and educate them on the topic.  
 There are various FP options available depending on the patient’s sex, age, 
pubertal status, relationship status, and personal preferences. However, it should be noted 
that some of the options available are still considered experimental.  
 Options available for post-pubescent females include oocyte and embryo 
cryopreservation. These methods involve ovarian stimulation, which often delays the start 
of cancer treatment.44 This process takes approximately two to six weeks.45 Hormonal 
medication, synthetic FSH or human menopausal gonadotropins, is used to stimulate the 
formation of multiple follicles in the ovary that contain eggs.44,46 A minor surgical 
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procedure, typically eight to 14 days after hormonal stimulation, is performed to remove 
the unfertilized eggs that will be frozen.44 Frozen eggs can later be fertilized with sperm 
in vitro and implanted into the uterus to achieve pregnancy. Approximately ninety 
percent of eggs survive freezing and thawing and about seventy-five percent can be 
successfully fertilized.46 The likelihood of becoming pregnant after implantation is 
roughly thirty to 60 percent, depending on the patient’s age at the time of egg freezing.46 
The younger the patient is at the time of oocyte retrieval, the higher the likelihood of 
having a live birth following implantation of a cryopreserved oocyte.46  
For female patients who have a partner or are willing to use donated sperm at the 
time of egg retrieval, the egg can be fertilized in vitro to create an embryo that is then 
cryoperserved.44 The embryo is then later implanted into the uterus when pregnancy is 
desired.  Cryopreservation of embryos has had greater success than cryopreservation of 
oocytes, yielding an increased percentage of live birth pregnancies.46  
Ovarian tissue cryopreservation is an option for females of all ages, including pre-
pubescent girls.44 This method of FP is currently considered experimental. Data on the 
outcomes of this FP method is currently limited, however, there have been approximately 
twenty-eight live births reported worldwide.45 Unlike oocyte and embryo 
cryopreservation, ovarian tissue cryopreservation does not require hormonal 
stimulation.44 This helps to eliminate the delay in treatment that can make FP unavailable 
to many patients. Ovarian tissue cryopreservation requires surgery to remove part or all 
of an ovary.44,47 Following oophorectomy, the ovarian tissue that contains the oocytes is 
cut into thin slices and frozen.47 Later, when fertility is desired, this tissue can be thawed 
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and re-implanted into a woman’s body, usually on the remaining ovary.47 Following the 
transplant, the implanted tissue produces hormones and eggs.44 
There is also active research in extracting the immature eggs from the removed 
ovarian tissue.44 The immature eggs can then be matured in the lab for use in in vitro 
fertilization.44 This method allows for re-implantation of a fertilized egg rather than the 
ovarian tissue.44 Currently, there have not been any successful pregnancies reported using 
this method.44 
An additional FP method that is available for females of all ages is ovarian 
transportation. This is a surgical procedure that can be performed on females who are at 
risk for infertility as a result of radiation induced ovarian damage. During this procedure, 
the ovaries are surgically moved higher in the abdomen, out of the field of radiation to 
minimize exposure and damage prior to radiation treatment.45 The success rate of this 
procedure in patients undergoing pelvic radiation is between seventy-nine to one hundred 
percent.45 This is not a viable option for patients at risk for infertility as a result of 
chemotherapy treatment. 
For postpubescent male patients with childhood cancer the most effective method 
to preserve fertility is sperm banking. For sperm banking, males produce a semen 
specimen through sexual stimulation.48 If a specimen cannot be obtained this way, sperm 
cells can be obtained through minor surgery or alternative stimulation methods, such as 
electroejaculation.48 Electroejaculation uses a probe attached to an electric current to 
induce ejaculation.42 Sperm banks are located across the country and there are also 
cryobanks that operate sperm banking by mail programs, making this method easily 
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accessible to patients and prevents delays in treatment.48 Donations can be made every 
24-48 hours.48 It is suggested that patients cryopreserve multiple specimens but even one 
sperm cell may be enough for conception to be achieved through Intracytoplasmic Sperm 
Injection.48 Approximately fifty percent of the sperm frozen will survive the freezing and 
thawing process.48 It is estimated that sperm can be frozen for several thousand years 
without damage.42 
Another FP option for post-pubescent males is testicular epididymal sperm 
extraction. This method is used for men who do not have mature sperm in the semen.48 
These patients may have sperm in their testicular tissue despite not having sperm in the 
semen.48 Through needle biopsy, individual sperm from the testes and/or the epididymis 
or a micro-dissection of the testicular tissue itself can be extracted.42,48 If found, sperm 
cells can be removed and either used immediately or frozen for future use with in vitro 
fertilization.42,48 Studies have revealed the presence of live sperm in up to forty-five 
percent of men who did not have sperm in the ejaculate after cancer treatment.48 Success 
rates, defined as acquisition of sperm, vary with biopsy techniques but range from 30% to 
70%.48 Testicular epididymal sperm extraction can be used prior to treatment or post-
treatment, although studies have shown higher success rates prior to treatment.42,48 In a 
study by New York Presbyterian Hospital, researchers were able to retrieve sperm in 
thirty-seven percent (27 of 73) of male cancer survivors.42 This method is a common 




An experimental option available for pre and post-pubescent males is testicular 
tissue cryopreservation. This method is like that of ovarian tissue cryopreservation in 
females. Testicular tissue is surgically removed, frozen, analyzed, and stored for future 
use.48 The testicular tissue contains stem cells which will be able to start 
spermatogenesis.42 Protocols are being developed to use the cryopreserved tissue to 
produce sperm in the laboratory or to re-implant the tissue years later.42 Due to the 
experimental nature of this procedure, it is only offered under Institutional Review Board 
(IRB) protocol at a few locations in the country limiting its use.48 There have been no live 
births to date in humans but animal studies show promise for future use.42,48 
 The ethics of pediatric FP in childhood cancer is a multifaceted topic and is 
unique to each patient. A full ethical discussion is beyond the scope of this paper but a 
few of the major ethical considerations that will be considered in the proposed study will 
be discussed further. One of the major factors that needs to be considered when deciding 
if FP is appropriate is the urgency at which treatment needs to be initiated. The timing of 
potential FP must be balanced with the initiation of potentially lifesaving cancer 
therapies.49 Some of the other major ethical considerations in pediatric FP for childhood 
cancer patients are beneficence, nonmaleficence, justice, and respect for autonomy. The 
pros and cons need to be weighed by the patient and/or their parents when considering 
FP. 
 Beneficence includes the benefit to the patient and society.49 The major benefit to 
the patient is that FP prior to the initiation of therapy may give them the chance to 
become a biological parent one day even if their cancer treatment renders them infertile.49 
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In addition to preserving fertility, some of the methods discussed have the ability to 
restore hormone production.49 Reproductive hormones have a variety of health benefits, 
including cardiogenic and bone health. From a psychological standpoint, FP can prevent 
or reduce the distress associated with future infertility.49 The main benefit to society is to 
further the research on pediatric FP.49 Conversely, FP procedures can be considered not 
medically necessary.49 
 Nonmaleficence means first do no harm.49 Despite the benefits to the patient 
discussed above, the procedures associated with FP carry risks of complications. First off, 
FP procedures can delay medically necessary and urgent treatments, such as 
chemotherapy or radiation, which relegates FP to a lower priority.29,49 These procedures 
can also be physically and psychologically distressing to the patient during an already 
physically and emotionally demanding time.49 These procedures also have side effects 
and small risks of complications associated with them.49 
 Justice, defined as equity in the healthcare system, is a major ethical concern of 
FP in childhood cancer patients. FP should be offered and discussed to provide patients 
with the best available information regarding the risks, benefits, and outcomes.49 There is 
an unequal allocation of FP resources within the country.49 Pre-pubescent children 
currently only have experimental methods of FP available. These procedures need to be 
performed at one of the few IRB approved sites. As well as access to resources, the costs 
associated with FP prohibits access for many patients (Table 4). Health insurance may 
not cover some or all aspects of FP costs, making out-of-pocket costs prohibitive to many 
patients and families.49 Due to the experimental nature of ovarian tissue and testicular 
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tissue cryopreservation, the costs may be reduced or waived.45  It is also necessary for 
patients and families to be aware of the future costs of reproductive medicine services 
when pregnancy is attempted.49 
Table 4. Approximate Expenses for Common Fertility Preservation Procedures42,45,48 
 
 Initial Procedural Cost Storage Fee (per year) 
Oocyte cryopreservation $10,000-$15,000 per 
cycle 
$275-$1000 
Embryo cryopreservation $10,000-$15,000 per 
cycle of IVF 
$350-$1000 
Ovarian tissue cryopreservation $10,000-$15,000 $300-$500 
Sperm banking $1,000 for analysis and 
freezing per donation 
$300-$500 




There are resources available to provide financial assistance to childhood cancer 
patients who wish to pursue FP. However, many providers and families are unaware of 
these options.49 Families, who are under a lot of stress during this time and want to 
initiate treatment as soon as possible to save their child, do not have the time to research 
and explore all of the options available to be able to provide FP from a financial 
standpoint. Some states have mandated coverage of infertility services by law. However, 
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pediatric patients generally do not meet the strict definition of infertility -- unable to 
conceive for greater than one year with unprotected intercourse -- and as a result face 
large out-of-pocket costs.49 A study out of Quebec reported that providing coverage for 
assisted reproductive therapy increased the number of sperm banking visits among 
patients with cancer.49 This study suggests that financial barriers are limiting access to 
and use of FP services.49 
   The other major ethical consideration for FP in childhood cancer patients is 
respect for autonomy. Many childhood cancer patients are too young to understand the 
implications of infertility and FP. In this regard, FP provides patients the ability to decide 
if and how they want to build a family at a later time in their lives.49 Preservation of full 
reproductive potential has been identified as a priority for previous survivors of 
childhood cancers.6,49,50 However, pediatric FP requires parental proxy decision 
making.49 If the patient is old enough to participate in the discussion, the patient’s wishes 
may differ from those of their parents and controversy may arise on how to proceed.49 
There may also be differing opinions among the parents.49 From a research standpoint, 
there is the ethical issue of using preserved tissue of a minor for research purposes.49 A 
decision must also be made about what to do with the preserved specimens if the child 
does not survive.49  
Aside from the ethical issues discussed above, each patient and family have their 
own individual values and religious beliefs that need to be considered. Patients and 




 There is limited research on the extent to which FP is discussed by pediatric 
oncologists and, of the research that is available, little of it touches on the actual content 
that is being discussed.7 The available data regarding infertility risk discussions and FP 
options is focused on adolescents and young adults with new cancer diagnoses. Of the 
studies conducted, the literature shows there is a lack of communication among 
physicians and childhood cancer patients/families about the potential risk of infertility 
and the available FP options.13  The American Society of Clinical Oncology released 
their guidelines for discussing FP in 2006. However, in 2009 two studies demonstrated 
suboptimal rates of FP discussions with patients of childbearing age.13 These two studies 
showed less than 60% of oncologists discussed fertility with patients/families and less 
than 40% of treating physicians referred patients interested in FP to reproductive 
specialists.13 In 2011, a nationwide survey of pediatric oncologists was published that 
ascertained practitioner attitudes and practice patterns in the wake of the ASCO 
recommendations’ release.50 The results showed that although 86%of responding 
pediatric oncologists agreed with the recommendation to refer all pubertal males to a 
reproductive specialist in advance of oncologic treatment, only 46% of respondents 
reported actually doing so more than half of the time.50 This study also revealed that only 
44% of practitioners reported familiarity with the ASCO recommendations and only 39% 
used the recommendations with more than half of their patients.50 The literature has 
demonstrated a variety of barriers that prevent these discussions from happening, 
including physicians not being comfortable discussing fertility, time constraints, 
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patients/families having an overload of information at the time of diagnosis, and lack of 
resources or institutional policies.13  
A study was conducted using medical records at four National Cancer Institute 
designated comprehensive cancer centers to evaluate the rates of documentation of 
infertility risk discussions, discussion of FP options, and referral to a fertility specialist in 
adolescent and young adult cancer patients age 18 to 45 years.13 A total of 231 patient 
records were included in this study.13 Results showed that, of the 61 patient records 
reviewed, 26% documented discussion of infertility risk, 24% documented discussion of 
FP options, and 13% documented referral to a fertility specialist.13 The records were less 
likely to contain evidence of infertility risk and FP option discussions for female patients 
(P = .030 and .004, respectively) and were also less likely to contain evidence of 
infertility risk discussion among Hispanic/Latino patients (P = .037).13 The 2013 update 
to the ASCO guidelines states that patients should not be excluded from consideration for 
discussion of FP for any reason, including parity, prognosis, age, and socioeconomic 
status.13,51 
A qualitative study using open-ended, in-depth interviews with 24 pediatric 
oncologists in Florida at 13 children’s cancer centers was conducted to better understand 
factors that influence the discussion of FP issues among pediatric oncologists and 
patients/families.7 This study revealed the main factors associated with a discussion of FP 
options were: (1) physician factors that contribute to communication issues with FP 
discussion (e.g., awareness and sense of comfort in discussing issues, perceptions of the 
priority); (2) parent factors (e.g., receptiveness and cultural background); (3) patient 
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factors (e.g., receptiveness and age); and (4) institutional factors (e.g., referral sites and 
practice guidelines).7 This study noted that about half of the oncologists who responded 
stated they would like to learn more about FP, especially about the options available for 
females, so they could better explain FP methods to their patients.7 All of the physicians 
reported having not received any formal training in discussing FP and that they model 
their approach from those of attendings they observed during fellowship.7 Approximately 
half the respondents reported that they would like institutional guidelines regarding FP.7 
When asked how physicians prioritize the discussion of FP with newly diagnosed patients 
relative to other issues, about half ranked the priority as medium stating that issues 
assessing the disease and establishing treatment plans were higher.7 About a quarter 
ranked the priority as high stating it was a quality of life issue and about a quarter ranked 
it having low priority citing the lack of good options for females or very young patients in 
general.7 Physicians stated that the inability to delay treatment to pursue FP did not deter 
physicians from discussing it, although all physicians said their female patients could not 
delay treatment for the 6-8 weeks necessary for ovarian hyperstimulation, while male 
patients could delay treatment a couple days to bank sperm.7 Healthcare providers 
reported looking for cues from parents’ body language to gauge their comfort with the 
discussion and ended it when parents seemed upset.7 Approximately half of the 
healthcare providers believed parents wanted information about FP and the other half 
believed parents were either uncomfortable with the discussion or solely focused on their 
child’s treatment and prognosis and did not wish to consider FP.7  
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Physicians reported that a large barrier to FP discussion is that parents are in 
shock due to the cancer diagnosis and this emotional state prevents them from being able 
to focus on anything other than their child’s survival.7 The providers believed that 
patients and their families are receiving so much information during the time of 
diagnosis, making them unable to retain most of the information presented to them.7 
Some of the providers reported discussing FP at follow-up consultations rather than at the 
time of initial diagnosis so that parents have time to process the diagnosis and treatment 
plan before considering the risk of infertility.7 Approximately one-third of the providers 
reported routinely giving educational literature about FP options to patients.7 The other 
two-thirds, who do not routinely give educational materials, cited a lack of materials or 
felt the current materials available are not appropriate for their patient population.7 All of 
respondents agreed there is a need for low-literacy and culturally appropriate materials.7 
Approximately 75% of the respondents said they believed that, if parents had something 
to read and reflect on, they would find FP information more relevant and return to ask 
about it for their child.7 
Overall, the current literature suggests that there is room to improve the frequency 
at which these important conversations are occurring, the quality of the conversations, 
and then to increase the number of patients being referred to a fertility specialist. Updates 
to the ASCO guidelines for fertility in 2013 concluded that more research is needed to 
establish the best method to disseminate information and to determine the best time to 
talk with patients about their options.51 They recommended that the discussion should be 
part of the comprehensive treatment planning process.51 The panel strongly encouraged 
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health care providers to have an open dialogue with patients or parents/guardians of 
children anticipating cancer treatment who express interest in FP, as well as those who 
are ambivalent, and refer them as expeditiously as possible to a reproductive specialist.51  
Another important line of inquiry is to understand survivors’ and parents’ 
attitudes and emotions regarding cancer-related infertility and FP options.30 Retrospective 
studies confirm that FP is important to childhood cancer patients and their families. The 
majority of studies have shown that having cancer during childhood increases the value 
that survivors place on family ties.30,52 Some survivors of childhood cancer describe the 
loss of fertility as being as painful as facing the cancer itself.6,52 Many, if not most, 
survivors of childhood cancer do not know their fertility status.30 
A qualitative exploratory study used focus groups to assess (1) short- and long-
term concerns at the time of cancer diagnosis, (2) attitudes about fertility at the time of 
diagnosis and presently, and (3) reactions to a proposed clinical research study in ovarian 
tissue preservation.6 The study consisted of ten female survivors diagnosed between the 
ages of 13 and 21 and ten parents of survivors.6 The median age of the survivors at the 
time of diagnosis was 14.5 years with a range of 13-21 years.6 All of the patients had 
received treatment that could impact their fertility.6 Eight of the ten survivors had 
received chemotherapy and all had received radiation.6 At the time of the study, five of 
the ten survivors were unaware of their present fertility status.6 A total of three survivors 
had attempted to conceive, all successful without reproductive medicine or procedures.6 
The median age of the ten parents was 54 years with a range of 53 to 67 years.6 Three of 
the parents were male and seven were female.6 
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The first topic of the focus group was short- and long-term concerns at the time of 
cancer diagnosis.6 At the initial time of diagnosis, survivors’ short-term concerns were on 
appearance (e.g. hair loss), feeling sick, missing out on academic and extracurricular 
activities in school, and the social impact of cancer (e.g. how friends would treat them).6 
Overlap among survivors in regards to long-term concerns focused on dying, relapse, and 
infertility.6 The survivors reported that at the time of diagnosis their focus was on getting 
through their treatment, rather than worrying about long-term health problems and the 
late effects of cancer treatment..6 Survivors reported that their physicians and nurses 
focused on short-term treatment side-effects, like hair loss and weight gain, rather than 
long-term consequences, such as infertility, which they reported were rarely discussed 
prior to treatment.6 Survivors and parents agreed that when fertility was discussed it was 
during treatment, when faced with decisions regarding location and/or additional courses 
of radiation, or after treatment, when describing the potential for late effects.6 
The focus groups that were composed of the parents of survivors mentioned that 
their main priority and concern was their child’s survival.6 In terms of infertility, the 
parents responded similarly to the survivors where some mentioned their daughter’s 
fertility was a concern at the time of diagnosis and others, particularly fathers, reported 
that it “wasn’t even on the radar screen”.6 Some of the parents reported that they recalled 
discussing fertility and some did not.6 Some of the parents also wished they had known 
more about the possibility of their child’s infertility and what options were available prior 
to the first treatment.6 The parents acknowledged that they felt overwhelmed by the 
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amount of information that was presented to them at the time of diagnosis and that it was 
hard to remember and comprehend it all.6 
The second topic of the focus group was the importance of fertility, at the time of 
diagnosis and currently.6 Most survivors reported that, at the time of diagnosis, fertility 
was not an issue they considered important.6 Most of the survivors reported they did not 
recall discussing fertility with their physicians, while others reported how disconcerting it 
was to learn about the risk of infertility or that they were infertile.6 The survivors 
acknowledged that fertility gained importance for them when they were told their ability 
to have biologic children was going to be threatened.6 Currently, as adults, almost all the 
survivors endorsed the importance of fertility.6 Parents, overall, felt that fertility was not 
very important before or at the time of their child’s diagnosis.6 A few mothers, however, 
agreed that “fertility is always a concern when one has daughters, regardless of age.”6 
The parents acknowledged that they had given little thought to their daughter’s fertility 
and assumed their child would be fertile.6 Despite how they viewed the importance of 
fertility at diagnosis, the majority of parents commented that the importance of fertility 
has now increased and has become a current issue for their daughter.6 Overall, parents 
believed that for maximum acceptance FP should be presented to parents as part of their 
child’s treatment package when discussing treatment optins.6  
A similar study was conducted with male survivors of childhood cancer and 
parents of male childhood cancer survivors. The purpose of the study was to determine 
the preferences, concerns, and attitudes toward FP of adult male survivors of childhood 
cancer and their parents.50 A total of 15 male survivors of childhood cancer and 7 parents 
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of survivors were included in the study.50 The mean age of the patients at time of 
diagnosis was 14 years of age with a range of 10-20 years and mean age at the time of the 
study was 35 years with a range of 25-47 years of age. As with the previous study, semi-
structured focus groups were conducted to elicit participant’s past and present attitudes 
towards, preferences for, and concerns regarding FP for pediatric cancer patients.50  
The results were very similar to those found in females survivors with common 
themes most frequently discussed being survivors concern regarding long-term treatment 
effects and a retrospective desire for the risk of fertility to have been discussed at the time 
they were diagnosed with cancer.50 Parental themes included the same retrospective 
regret and desire, as well as reliance upon the treating oncologist for direction in selecting 
the course of treatment and an acknowledgment that input from a specialist in FP would 
have been beneficial.50 The parents regret was accompanied by a strong sense of guilt 
that they had not thought to raise the issue of fertility in treatment discussions.50 As in the 
prior study, parents reported they deferred to the treating oncologist throughout the 
decision-making process regarding matters of care and treatment, including FP.50 
Survivors and parents in this study agreed with those in the female study that, although 
fertility was not a concern they had at the time of diagnosis, it becomes a paramount 
concern later in life and, thus, FP discussions should be routinely incorporated in the 
clinical context of childhood cancer diagnosis.50 
This study also calls into question the validity of the provider perception that 
parents are embarrassed or made uncomfortable by FP discussions.50 Physicians report 
using visual clues of parental body language to determine if a parent is interested in 
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hearing about FP options. The parents in this focus group who were involved in FP 
discussions rarely recounted any feeling of embarrassment or discomfort experienced 
from the discussion of their children’s fertility prospects or the concept of sperm 
banking.50 In contrast, as in other studies, parents report that FP discussions provided a 
sense of hope, with the implied expectation that their children could overcome their 
childhood cancer and survive long enough for future fertility to be of concern.50 A 
qualitative investigation of the attitudes of adolescent and young adult oncology patients 
and their parents towards sperm cryopreservation used a comfort ratings scale to assess if 
providers accurately estimate patients/parents comfort level with discussing this topic.50,53 
This study used a scale from 1 to 5, with 5 being completely comfortable.50,53 A mean 
comfort score of 3.34 was elicited from the patients and 3.78 from their parents.50,53 The 
above studies support the idea that patient and parent discomfort levels are often 
overestimated by providers.53,53 
Existing research 
With the increased survival rates of childhood cancers, it is becoming increasingly 
important to inform patients of the risk of late effects and when possible intervene to 
minimize these risks. Recent advances in the field of FP allow a greater number of 
patients to be eligible to benefit from these options. The current literature suggests that 
many childhood cancer patients and their families are either not being told about the risk 
of infertility due to cancer treatment or are inadequately having FP options discussed 
prior to the initiation of treatment. There is room to improve the patient-parent-clinician 
communication and decision making of FP among children newly diagnosed with cancer.  
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The use of a FP decision aid (DA) could potentially help ameliorate the 
knowledge gap cancer patients and/or their caregivers have reported regarding the risk of 
infertility and their FP options. The use of a DA (1) allows patients/families to receive 
standardized information at a level that is easily understood on the benefits and risks of 
the options available, (2) allows the patients/families to have time to consider the options 
and elicit important personal ethical and religious considerations of each option, and 
ultimately (3) leads to a shared decision of an option that aligns with the families’ well-
informed preferences.54 Decision aids have been widely tested in practice. Although 
previous DA testing was predominantly in adult medicine, pediatric practices are now 
adopting the use of DAs.  
The use of DAs in FP has previously been tested and shows promising results for 
further development and use among a broader group of patients. Decision aids have been 
developed for women with breast cancer and most recently a DA for women of 
reproductive age that addresses all cancer types.10,11 
One of the first studies that evaluated the use of a DA in FP was conducted with 
young women newly diagnosed with breast cancer.9 The study goals were to  (1) compare 
changes in decision-related outcomes, including decision conflict about fertility treatment 
decisions (primary outcome) and knowledge, over time; (2) compare decision-related 
outcomes, including decisional regret about treatment decisions, and informed choice at 1 
and 12 months post diagnosis; and (3) examine potential changes in anxiety and 
depression as a result of the use of the DA compared to usual care.9 The DA used in this 
study was a booklet that contained breast cancer and female infertility educational 
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information and included a discussion of the different FP options available.9 As a values 
clarification exercise, the DA listed the advantages and disadvantages of each treatment 
option and asked participants to rate each option as one they were either leaning towards 
or against.9  
Participants were women interested in having a child, aged 18-40 years of age, 
with a new diagnosis of early breast cancer stage I, II, or III, excluding ductal carcinoma 
in situ and metastatic disease at 19 oncology clinics around Australia.9 Final results 
included 60 women in the control group who received a guide on early breast cancer that 
was currently distributed to women at many clinics as part of usual care and 36 in the 
intervention group who received the DA.9 Measures that were recorded included 
demographic, reproductive and disease-related data, intended decision about fertility 
treatment, decisional conflict scale, knowledge of fertility-related information, hospital 
anxiety and depression scale, a multidimensional measure of informed choice, use of 
materials, satisfactions with and helpfulness of educational materials, actual decision, 
partner’s involvement, clinician discussion and referral, and decision regret scale.9 
Participants who received the DA had a reduction in decisional conflict compared to  
those in the usual care group.9  At 12 months, the decisional conflict scale scores were 
15.30 units lower in the DA group (P = 0.02).9 Participants in the DA group had a 
significant increase in fertility-related knowledge.9 No significant difference between 
groups were reported at 1 month or 12 months in terms of the proportion of participants 
who made an informed versus an uninformed choice about fertility, as well as in 
participants’ anxiety and depression scales.9 At 12 months, participants who received the 
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DA had significantly lower decisional regret than those in the control group after 
adjusting for education.9 Compared to the control group, participants who received the 
DA reported a significant increase in their satisfaction levels of the materials they 
received about the impact of breast cancer on fertility (χ2 = 15.49; P < 0.001) and on the 
different fertility options available (χ2 = 10.66; P = 0.005).9 Participants also scored the 
DA more highly on a helpfulness scale in terms of making fertility-related decisions (χ2 = 
0.61; P = 0.002).9 In terms of the number of referrals to a fertility specialist, 62% of 
participants who received the DA and 55.6% of participants in the usual care group were 
referred to a fertility specialist (χ2 =0.48; P = 0.49).9 Of those who received a referral to a 
fertility specialist, 97.7% of participants in the DA group and 91.4% of controls consulted 
or were planning to see a fertility specialist (χ2 = 0.71; P= 0.40).9 The researchers of this 
study concluded that, based on the reduced decisional conflict and regret with respect to 
personal values, improved fertility-related knowledge, and improved satisfaction with the 
information received, this DA should be widely distributed to young breast cancer 
patients prior to chemotherapy who are considering future pregnancies.9 This study may 
reflect a selection bias in the clinicians who participated in the study. This is evident by 
the finding that most oncologists discussed fertility with all breast cancer patients of 
reproductive age, whereas previous studies documented this rate to be approximately 
70%.9 Past studies also reported an approximate referral rate to a fertility specialist of 
25%, much lower than that reported in this study which again could be due to selection 
bias of the clinicians who participated.9 An additional limitation of this study was the 
non-randomized design which can also lead to bias.9   
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 The Pathways DA for FP was later developed and is currently being tested for 
women with cancer of all types.11 This DA is in the form of a website. The Pathways DA 
provides (1) up-to-date evidence and descriptions of FP and other family-building 
options, tailored to cancer type; (2) structured guidance to support personalizing the 
information and informed decision making; and (3) a printable summary to help women 
prepare for discussions with their oncologist and/or fertility specialist.10,11 The initial field 
testing of the DA with 20 female survivors of cancer indicated that the DA when used in 
combination with a fertility specialist consultation improved women’s knowledge and 
decision-making.11 The primary aim of the Pathways study is to assess the effect of a 
multicomponent oncofertility decision support intervention on female oncology patients’  
decisional conflict regarding FP.10 The multicomponent intervention includes an 
educational seminar for oncology providers, providing the patients access to the 
Pathways DA website, and navigation support in the form of follow-up telephone 
decision counselling.10,11 The usual care includes oncology consultation and an offer for a 
referral to a FP specialist, if desired.10 The secondary aim is to assess patients’ decision-
making process and decision quality.10 Assessment of the decision-making process 
includes patient preparation for decision-making, decision self-efficacy, and 
satisfaction.10 Assessment of the decisional quality includes FP knowledge, clarity of 
patients’ values and congruence of preferences with the decision about whether to accept 
FP referral and/or FP treatment.10 The study protocol was based on the underlying 
decision-making and cognitive psychology theories of the Ottawa Decision Support 
Framework and followed the quality guidelines of the International Patient Decision Aid 
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Standards (IPDAS) Collaboration.10 This study is being conducted at four University of 
Texas MD Anderson Cancer Center Houston Area Location oncology clinics.10 Two sites 
serve as the control groups and the other two sites serve as the experimental groups.10 
The Pathways study includes women aged 18 to 45 years old with a new diagnosis of a 
breast tumor, female genital system tumor, colorectal tumor, lymphoma, and/or myeloma 
who are at risk of cancer-related infertility.10 Participants are being asked to complete 
online questionnaires at baseline, 1 week, and 2 months.10 
 The primary measure is decisional conflict, assessed pre/postintervention using 
the 16-item Decisional Conflict Scale.10 The study assesses participant’s decision-making 
processes using the Decision Self-efficacy Scale, Preparation for Decision Making Scale, 
and open-ended questions assessing other decision-making factors (e.g. three primary 
influences on their decision, role of spouse/partner in decision-making, etc.).10 
Participants’ decision quality is assessed using the FP Knowledge Scale, Values 
Clarification Learning Scale, and Strength of Preference for Referral/Treatment(s) Scales, 
as well as an assessment of the concordance of participants’ preferences with subsequent 
treatments scheduled or completed by 2 months.10  
Pathways aims to shift the conversation about the risk of infertility and FP options 
upstream  by (1) offering providers training to enable and motivate them to introduce the 
concept of FP, as well as a trusted, high-quality website to which they can refer women 
and (2) by providing women with high-quality information and personal decision-making 
activities, tailored to their cancer type, as well as telephone counselling to support 
decision-making and referral, when desired.10 The Pathways study has the potential to 
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improve the care of female patients of reproductive age who are given a new diagnosis of 
cancer by increasing their awareness and knowledge of their risk of infertility and the FP 
options available to them.10  Increased awareness and knowledge can lead to better 
communication, improved decision quality, increased satisfaction with their decision, and 
decreased rates of long-term infertility-related distress, decision regret and 
dissatisfaction.10 
Novel research, such as the Pathways study, is being conducted for FP in adult 
medicine, however, there is a lag in incorporating these research ideas into pediatric 
medicine. With advancing technology improving the options for FP in childhood cancer 
patients, it is necessary to improve the effectiveness of the FP decision making process 
for these patients. The use of a DA, like that developed in the Pathways study, could 







The development of the childhood cancer fertility preservation decision aid will have four 
phases: (1) scoping and design, (2) prototype development, (3) ‘alpha’ testing with 
patient representatives and clinician representatives in an iterative process, and (4) field-
testing. The decision aid will be developed following the Model Development Process for 
Decision Aids,55 in accordance with the IPDAS guidelines and based on behavioral and 
decision-making theories underlying the Ottawa Decision Support Framework. It will be 
field tested in a single-center pilot study. Design and field testing will be modeled off the 
Pathways fertility preservation decision aid website for women with cancer.11 Using an 
adapted user-centered design process the steering group and design team will design and 
optimize the patient decision aid through review and revision with clinicians and 
childhood cancer survivors. Field-testing will be completed with newly diagnosed 
childhood cancer patients to assess participants’ decision quality, using the Fertility 
Preservation Knowledge Scale, and participants’ decisional conflict, assessed using a 16-
item Decisional Conflict Scale pre- and post-intervention.  
Scoping and design 
Scope 
The childhood cancer fertility preservation decision aid will be developed for English-
speaking, newly diagnosed childhood cancer patients, male or female, age 15 to 19 years 
of age with any form of childhood cancer. Childhood cancer patients are at risk for 
treatment associated infertility and have to decide at a young age, along with their 
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caregivers depending on their age, about their preference to pursue fertility preservation. 
The primary goal of the decision aid is to improve participants’ decision quality by 
providing education on fertility preservation. The secondary goal is to reduce 
participants’ decisional conflict.  
Steering 1 
All phases of the project and versions of the decision aid will be reviewed and approved 
by the steering group and the research and design team. The steering group will be a 
small group responsible for overseeing this project. The steering group will be composed 
of three patient representatives, three pediatric oncologists, two reproductive 
endocrinologists, one member from the Ethics Committee, and one child life specialist. 
Eligible patient representatives will be English speaking childhood cancer survivors 
treated at St. Jude Children’s Research Hospital, enrolled in the St. Jude LIFE Study,56 
and received cancer treatment, within the last 15 years, with at least one of the following 
between the ages of 15 and 19 years of age: chemotherapy, surgery on a reproductive 
organ, surgery or radiation to the hypothalamus or pituitary gland, hormonal therapy, 
and/or pelvic radiation.11  The three pediatric oncologists and two fertility specialists will 
be current clinicians at St. Jude Children’s Research Hospital. There will also be a 
consultant from the St. Jude Children’s Research Hospital Ethics Committee and a child 
life specialist.  
The core research and design team will be responsible for conducting the 
literature review, conducting all interviews and focus groups, as well as the design and 
development of the decision aid prototype. This team will include study designer, Jessica 
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Grasso, and St. Jude Children’s Research Hospital employees including 5 reproductive 
endocrinologists, 5 pediatric oncologists, 5 research scientists, 3 research coordinators 
from the St. Jude LIFE Study, 4 data analysists from the St. Jude LIFE Study, 2 graphic 
designers/web programmers, and 15 research assistants.  
Design participants  
Participants involved in the design phase will include patient representatives and clinician 
representatives recruited from St. Jude Children’s Research Hospital. Eligible patient 
representatives must meet the same eligibility criteria as the patient representatives on the 
steering committee. For the research and design of the decision aid, sampling size will be 
based on a sample of convenience. It will be focused on determining the patients’ and 
clinicians’ views on decisional needs. It is estimated that 50 patient representatives will 
be recruited for the development and design of the decision aid. Having fifty patient 
representatives allows for a large number of opinions to be considered while remaining a 
feasible number to conduct needs assessment interviews on. This sample size is about 
equal to, or greater than, the sample size used in the development of many other decision 
aids. Clinician representatives will include St. Jude Children’s Research Hospital 
pediatric oncologists, mid-level oncology providers, and fertility specialists not already a 
member of the steering committee or the research and design team. It is estimated that 20 
clinician representatives (10 oncology providers and 10 fertility specialists) will be 
recruited for the development and design of the decision aid. All participants will provide 




Design participant recruitment 
The St. Jude LIFE Study has more than 4,300 participants to date to sample from. An 
email will be sent to all eligible participants in the St. Jude LIFE Study explaining the 
study and the estimated time commitment should they choose to participate. The email 
will contain an online submission form to enter their name, contact number to be reached 
at, email address, and a calendar with available times to select for a phone interview. The 
first 30 females and the first 30 males who submit their information and complete the 
needs assessment will be included in the study and asked to participate in the alpha 
testing of the decision aid. Sixty patient representatives will be enrolled with the goal of 
fifty patient representatives completing all aspects of the needs assessment and alpha 
testing. Clinician representatives will be approached in person at St. Jude Children’s 
Research Hospital and offered to participate. All participants who complete the needs 
assessment interviews and all phases of the alpha testing will receive a $50 Amazon gift 
card. 
Design data collection 
Design 1: Assess views of patient representatives on decisional needs 
Needs assessment studies will be conducted through the use of semi-structured and in-
depth phone interviews led by trained moderators. The goal is to elicit the views of the 
patient representatives on decisional needs surrounding fertility preservation in childhood 
cancer. The needs assessment study will elicit responses on information needs, fertility 
service, and preservation needs. Informational needs will include assessment of whether 
patient representatives recall receiving information about fertility treatment and 
preservation. This will include who provided the information, how the information was 
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presented, if the information was helpful, the timing of the information presentation, 
satisfaction with the timing, and feedback on how the process could have been improved. 
For participants who indicate that they did not receive information, they will be asked if 
they would have liked to receive information. If yes, they will be asked what topics 
would have been beneficial to receive information on. Patient representatives will also be 
asked about their fertility service and preservation needs including whether they took 
measures to preserve their fertility. For those who answer yes, they will be asked 
who/what influenced their decision. Those who answer no, in addition to who/what 
influenced their decision, will be asked about any barriers they faced with fertility 
preservation. Patient representative interviews are expected to last thirty minutes to one 
hour. Telephone calls will be recorded and stored on a secure computer drive.  
Design 2: Assess clinicians’ views on patients’ needs about their preference to pursue 
fertility preservation 
Needs assessment studies will be conducted through the use of semi-structured focus 
groups and in-depth interviews led by trained moderators. The goal is to elicit providers’ 
views on decisional needs surrounding fertility preservation in childhood cancer. This 
will include what information they feel needs to be shared with patients, how to best 
provide the information, and the timing of the information sharing. Focus groups and in-
depth interviews are expected to last approximately one hour and will be recorded and 
stored on a secure computer drive.  
Design 3: Determine format and distribution plan 
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Based on the needs assessment findings from Pathways, on which this study is modeled, 
a decision aid with a web-based format that customizes the information based on gender 
and cancer diagnosis, provides lay language definitions, and can be delivered to patients 
in the clinic or at home will be developed. The treating oncologist will refer patients to 
the decision aid website after their initial diagnosis to help them become aware of the 
potential fertility risks and consider whether they want to accept a referral to a fertility 
specialist. Patients will be given a unique login and password to access the decision aid. 
The website will recall where participants left off so that they can complete the decision 
aid at their own pace. The decision aid will be designed for the patient to go through 
alone or with their caregiver based on their preference. One section will be designed for 
the patient to go through alone, or with a child life specialist, to provide the patient some 
time for private reflection of their values, desire to be a biological parent in the future, 
preferences, and concerns. An optional section will be included at that end that is 
designed for the caregiver to go through to reflect on their values, preferences, and 
concerns. Patients may revisit the site at any time to review the information, assess their 
values and preferences, and note questions to discuss with their provider(s).11  
Design 4: Review and synthesize evidence 
Based on the needs assessment studies the research team will identify content themes, 
key messages, and design needs for all potential users.11 In line with the IPDAS 
framework, a comprehensive literature review on fertility preservation in childhood 
cancer will be completed using Medline and EMBASE. The search algorithm will be as 
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follows: (“cancer” OR “neoplasm” (MeSH term)) AND “fertility” AND (“child” (MeSH 
term)).  
Protype development 
From the information gathered in the literature review, the providers’ clinical knowledge, 
and the information gathered during the needs assessment studies, the research and 
design team will create a design strategies map. This will include a prioritized list of key 
users’ needs and a list of proposed theory- and evidence-based information, support, and 
features to meet each need.11 From this design strategy map a decision aid draft will be 
developed with the help of the graphic designer/web programmer to model that of the 
Pathways decision aid. Pathways values clarification exercises11 will be modified for use 
with our study population. The decision aid will provide information on fertility, the risk 
of treatment-related infertility, information on the fertility preservation options available, 
the benefits and risks of each option, and the modified values clarification exercises. The 
website will have hover-over definitions of medical terms.11 The website will provide 
links to a glossary, related sources, and all references.11 The decision aid will also 
provide an explanation of the referral process and a searchable map of fertility specialists 
for childhood cancer patients. After the information sections, the individual section 
designed for the patient to go through alone or with a child life specialist, as well as the 
optional section for the caregiver will be designed to facilitate action planning. The 
patient and caregiver will separately be invited to re-assess their values, indicate which 
treatment/family-building preferences they are leaning towards, reflect on how they are 
feeling about this decision, and document remaining questions and follow-up items.11 
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The patient and caregiver will each be provided a printable Personal Information Page 
that can be used to support discussions with each other and with their provider(s).  
 The decision aid will be written at an eighth-grade reading level. The website will 
be coded using responsive design to automatically adjust presentation for desktops, 
laptops, and tablets using WordPress (©AUTOMATTIC 2016) to facilitate easy 
updating.11 A MySQL database will be used to collect each patient’s responses to the 
values, preferences, and open-ended questions to create a Personal Decision Summary 
that can be saved and printed to discuss with their provider(s).11 The website will monitor 
website usability (i.e. time spent viewing the website, revisit rates, error rates) and how 
participants interact with the interactive features (i.e. which content participants focused 
on, engagement with open-ended text areas, responses on the learning scales).  
Alpha testing 
Alpha testing 1: With patient representatives to check comprehensibility and 
acceptability 
Using Google Hangouts screen sharing feature, patient representatives will be presented 
the storyboard by a trained interviewer using the ThinkAloud techinque57 and asked to 
describe their thoughts including terminology they do not understand, information/images 
that caught their attention, missing information, and any additional suggestions for 
improvement.11 
Alpha testing 2: With clinicians to check acceptability and feasibility 
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Once the initial storyboard design is complete, internal and external review (10 
oncologists at St. Jude Children’s Research Hospital and 10 reproductive 
endocrinologists at Boston IVF) will assess the accuracy of the clinical content.11 
Steering 2 
The results from alpha testing will be reviewed by the steering group. If necessary, the 
decision aid will be redrafted and redesigned. If redraft or redesign is necessary, alpha 
testing will then be repeated in an iterative process.  The research team and steering 
group will review the website protype, make minor revision to improve flow, and 
approve it for field-testing. Once the decision aid has completed the iterative review 
process and has been approved by the steering committee, field testing will be performed 
on patients to determine the effectiveness of the decision aid.  
Beta testing 
Beta testing design 
Field testing of the childhood cancer fertility preservation decision aid will be conducted 
using a pre-intervention/post-intervention survey design.  
Beta testing study population and sampling  
The source population will be patients at St. Jude Children’s Research Hospital. All 
newly diagnosed childhood cancer patients between the ages of 15 and 19 years of age 
being treated at St. Jude Children’s Research Hospital over a 3-month period will be 
eligible to participate in the study. To be eligible patient’s anticipated treatment plan must 
include at least one of the following: chemotherapy, surgery on a reproductive organ, 
surgery or radiation to the hypothalamus or pituitary gland, hormonal therapy, and/or 
pelvic radiation.11 Patients must be able to read, write, and speak English. St. Jude 
 
59 
Children’s Research hospital sees about 7,500 patients annually.58 It is estimated that in 
2018, 15,590 children ages birth to 19 years old will be diagnosed with childhood 
cancer.18 Of these patients, approximately 5,000 patients will be between the ages of 15 
and 19 years of age.18 Assuming similar proportions in the population seen at St. Jude 
Children’s Research Hospital, approximately 2,400 patients between the ages of 15 and 
19 years of age will be seen at St. Jude’s Children Research Hospital annually or about 
200 patients per month. With a 3-month testing period and conservatively assuming a 
50% participation rate, a sample size of 300 patients will be used for field testing. The 
primary outcome of decision quality will be analyzed using a one-group paired t-test. In 
the development and field testing of the Pathways decision aid, patients scored an 
average of 8.2 out of 13 (SD 1.6) on the Fertility Preservation Knowledge Scale.11 
Assuming a similar standard deviation and using a default within-subject correlation of 
0.875, 300 patients on each study arm will provide an approximately 80% power with a 
two-sided significance level of 0.05 to detect a mean difference of 0.13 in the scores on 
the Fertility Preservation Knowledge Scale before and after using the decision aid.59 
Beta testing intervention 
All patients who provide informed consent to participate in the study will receive 
intervention with the decision aid website. The treating oncologist will refer patients to 
the decision aid website after their initial diagnosis to help them become aware of the 
potential fertility risks and consider whether they want to accept a referral to a fertility 
specialist. Participants will be given a unique login and password to access the decision 
aid website. Once logged in, participants will complete pre-intervention testing to assess 
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their decision quality and decisional conflict. After completion of the pre-intervention 
testing, access will be given to view and complete the decision aid. Once the decision is 
complete and the participant’s Personal Information Page has been generated, access will 
be given to the post-intervention testing.  
Beta testing study variables and measures  
Pre- and post-intervention assessment of participants’ decision quality will be assessed 
using an adapted version of the Fertility Preservation Knowledge Scale originally used 
for fertility preservation in adult women.60 This scale ranges from 0-13. One point is 
allocated for each correct answer. The secondary aim is to assess participants’ decisional 
conflict. This will be measured using the 16-item Decisional Conflict Scale61 pre- and 
post-intervention. This scale ranges from 0-100. In this study, participant refers to the 
patient with childhood cancer. The patient will be asked to complete the scales 
independent of their caregivers to ensure the patient’s knowledge and decisional conflict 
is assessed, not the caregiver’s. Patient demographics including age, gender, and type of 
childhood cancer will be collected. This information will be stored and may be used to 
further stratify the results in future studies.  
Beta testing recruitment  
Following the initial diagnosis, oncologists will offer all patients ages 15-19 years of age 
the option to participate in the study. If patients express interest, a research assistant will 
be paged to come to the clinic to get informed consent from the patient and caregiver 
when necessary. 
Beta testing data collection 
 
61 
Participants will complete the pre- and post-intervention Fertility Preservation 
Knowledge Scale and the Decisional Conflict Scale online using the unique login 
information provided to access the decision aid. Pre- and post-decision aid study data as 
well as patient demographics will be collected using Research Electronic Data Capture 
(REDCap). 
Beta testing data analysis 
Data will be de-identified and analyzed using SPSS Statistics (v 23, IBM 2016).10 Scores 
from the Fertility Preservation Knowledge Scale will be compared between individual 
patient’s pre- and post-intervention test scores. The mean and standard deviation will be 
calculated. A one-group, paired t-test will be used to determine if the difference between 
pre- and post-intervention test scores is significant. Although the Fertility Preservation 
Knowledge Scale ranges from 0-13, the t-test is robust against a non-normal distribution 
when the sample size is appropriately large. The primary outcome measure for decisional 
conflict will be the percent of participants who score <25 on the Decisional Conflict 
Scale. Pre- and post-intervention test scores will be compared with respect to the change 
from baseline in the percent of patients who score <25 on the Decisional Conflict Scale. 
The data will be analyzed using the McNemar’s chi-squared test.  
The website will also monitor website usability (i.e. time spent viewing the 
website and revisit rates) and how participants interact with the interactive features (i.e. 
which content participants focused on, engagement with open-ended text areas, responses 
on the learning scales). These results will be stored and may be used to further stratify the 




The research team will analyze the field test results and participant responses. The 
graphic designer/web programmer will revise the website to address participant feedback. 
After revisions are made, an additional 5 oncologists at St. Jude Children’s Research 
Hospital and 5 reproductive endocrinologists at Boston IVF will review the updated 
website for any final revisions to optimize the decision aid. The research team will then 
reevaluate the decision aid using the IPDAS guideless to ensure it meets the requirements 
for a high-quality decision aid. The research team and steering group will then review 
and approve the final decision aid website. 
Timeline 
The research, design, development, and field testing of the decision aid is estimated to 
take approximately 21 months. It will take approximately one month to form the steering 
group and the research and design team. The design phase is estimated to take one month 
to enroll the patient and clinician representatives, 3 months to complete all the needs 
assessment interviews/focus groups, and 3 months to analyze the data and complete the 
comprehensive literature review. It will take approximately 4 months to develop the 
decision aid protype. Alpha testing will take approximately one month per iterative 
review cycle. An estimate of 4 cycles will be needed. Field testing will take 
approximately 3 months for data collection and one month for data analysis. An 
additional one month will be needed for review by the steering group and finalization of 




Necessary equipment includes $2,500 of Amazon gift cards to be given to all participants 
involved in the alpha testing, WordPress, MySQL database, REDCap, SPSS Statistics, 
and office space in the St. Jude LIFE Study office. Key personnel required for the 
steering group includes 3 patient representatives enrolled in the St. Jude LIFE Study, 3 
pediatric oncologists from St. Jude Children’s Research Hospital, 2 reproductive 
endocrinologists from St. Jude Children’s Research Hospital, 1 member from the Ethics 
Committee, and 1 child life specialist. Key personnel for the research team includes 5 
reproductive endocrinologists from St. Jude Children’s Research Hospital, 5 pediatric 
oncologists from St. Jude Children’s Research Hospital, 5 research scientists, 3 research 
coordinators, 4 data analysists from the St. Jude LIFE Study, and 15 research assistants. 
The design team will be composed of two graphic designers/web programmers. Internal 
and external review will be conducted by 10 oncologists at St. Jude Children’s Research 
Hospital and 10 reproductive endocrinologists at Boston IVF. 
Institutional Review Board 
Prior to initiation, this study will be submitted to the IRB for full-board review. Full-
board review is required as the field testing will include participants that are under 18 
years of age and/or have been newly diagnosed with childhood cancer making them a 
vulnerable population. The study, however, has minimal risk and involves non-invasive 





The childhood cancer fertility preservation decision aid website will provide adolescents 
ages 15 to 19 years of age who are newly diagnosed with childhood cancer, up-to-date, 
objective information, tailored to their gender and cancer type. The information provided 
will be about the risk of treatment-related infertility and the fertility preservation options 
available. It will also provide interactive activities that help personalize the information, 
clarify their induvial values, and prepare them to have well informed discussions with 
their provider(s) about their fertility preferences. A limitation of the field testing of this 
decision aid is that there is not a control group to compare the findings to. This is an area 
for future study once the decision aid has passed field testing and has been finalized. An 
additional limitation is that this testing is being conducted at a single site. However, given 
patients come to St. Jude from all 50 states, as well as other countries, the results will 
likely be generalizable. The St. Jude LIFE study has a database of more than 4,300 
participants who are long-term survivors of childhood cancer. This provides a wide 
variety of potential participants to offer their insight to guide the development of the 
decision aid. Conducting the field testing at St. Jude Children’s Research Hospital allows 
for a larger sample size than has been used in most existing research for decision aid 
development and field testing. Most field testing for fertility preservation decision aid 
development has used survivors rather than newly diagnosed patients to avoid testing on 
a vulnerable population. This study aims to conduct field testing on newly diagnosed 




There is an increased number of survivors of childhood cancer living into adulthood. As 
survivors have gone on to live longer lives, there is more being learned about the late 
effects of cancer treatment. It is well understood that cancer treatment can lead to 
infertility. There are now multiple fertility preservation options available for both males 
and females. Despite the increased understanding of the risk of infertility and recent 
advances to fertility preservation, these services have been shown to be underutilized by 
newly diagnosed cancer patients. Cancer-related infertility has been shown to be a source 
of distress to cancer survivors. There is evidence to support the use of decision aids to 
inform, educate, and guide medical decisions. Research has shown that discussing 
fertility preservation improves survivors’ long-term outcomes, including quality of life 
and levels of decisional regret.11 Currently fertility preservation decision aids have been 
developed and proven effective for adult women with cancer. To date, there has not been 
a fertility preservation decision aid developed for use by adolescents newly diagnosed 
with childhood cancer. This study aims to develop and field test a fertility preservation 
decision aid to improve the decision quality of adolescents newly diagnosed with 
childhood cancer who are determining their preferences on accepting a referral to a 
fertility specialist. The use of a decision aid will lead adolescents with childhood cancer 
to have increased knowledge on the fertility preservation options available as well as 
lower levels of decisional conflict surrounding their fertility preferences. 
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Clinical and/or public health significance 
If the decision aid is effective, referral to the fertility preservation decision aid may 
become part of the routine practice of pediatric oncologists at the time of initial diagnosis 
of an adolescent with childhood cancer. If effective at improving decision quality and 
reducing decisional conflict, survivors may experience the long-term outcomes associated 
with discussing fertility preservation including improved quality of life and reduced 
levels of decisional regret. Future studies will explore the effect using the decision aid 
has on rate of referrals to fertility specialists, utilization of fertility preservation 
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